The company's shares (LLY) climbed 2.3% Tuesday to end at $988.62 a share, after closing at a record high of $966.64 on Monday. The rally has pushed Lilly's market capitalization up to $934.6 billion, ...
Lower prices for 15 drugs, including Ozempic and Wegovy, are expected to be announced by the end of the month. The price ...
The company's shares (LLY) climbed 2.5% in afternoon trading on Tuesday, after closing at a record high of $966.64 on Monday. That rally pushed Lilly's market capitalization up to $937 billion, ...
Sarah Hall is leaving her role as president of FCB Health New York. The 2025 MM+M Agency 100 honoree confirmed the personnel move in a statement to MM+M on Tuesday afternoon. “Sarah Hall has decided ...
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...
There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...
So it was the government shutdown and some insane comments from OpenAI about a government backstop because of gigantic ...
Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...
As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...
11hon MSN
Where Will Pfizer Be in 3 Years?
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...
Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...
That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback